Clinical Trial: A Phase 1, Open-Label, Randomized, Single-Dose Crossover Study to Evaluate the Potential Impact of High-fat Meal on the Pharmacokinetics of CRS3123 200 mg Capsule in Healthy Adult Participants

U.S., May 24 -- ClinicalTrials.gov registry received information related to the study (NCT06988423) titled 'A Phase 1, Open-Label, Randomized, Single-Dose Crossover Study to Evaluate the Potential Impact of High-fat Meal on the Pharmacokinetics of CRS3123 200 mg Capsule in Healthy Adult Participants' on May 16.

Brief Summary: This study will explore the potential effects of high-fat meal on the plasma pharmacokinetics (PK) of CRS3123 when administered as a single oral dose of 200 mg in healthy adult participants.

Study Start Date: May 09

Study Type: INTERVENTIONAL

Condition: Food Effect in Healthy Participants

Intervention: DRUG: CRS3123 200 mg capsule

CRS3123 200 mg capsule given as a single oral dose

Recruitment Status: ACTIVE_NO...